The Sanofi title is currently taking the thunder on the Paris stock exchange, while some managers are fleeing the file like the plague and the risks inherent in several drugs in development… In addition, the market fears certain legal proceedings targeting Zantac in the United States, which could lead to particularly costly legal decisions for the group.
(Boursier.com) — A purge as brutal as it is spectacular for a group of this size, Sanofi having lost nearly 20% in the space of 4 trading sessions! Those who like to take the market on the wrong foot will take the opportunity to place themselves on the call warrant DE000SN3SPT6 which aims for a return towards 100 euros at maturity in June 2023, which leaves time to turn around.
Price on the date of the board: €0.23
©2022 Boursier.com